This video highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.
In this video, Kimmie Ng, MD, MPH, of the Dana-Farber Cancer Institute in Boston, highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.
Patients on the trial were treated with mFOLFOX6 plus bevacizumab and were randomized 1:1 to either a high-dose vitamin D therapy (8,000 IU/day for 2 weeks as a loading dose, followed by 4,000 IU/day) or low-dose vitamin D (400 IU/day).
Ng presented the results (abstract 3506) at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.
